Biotech Startup Breeds Blight Tolerant American Chestnut with Long-Term Viability

At the intersection of big data, forestry, and genomics, a biotech startup has birthed a generation of “elite” blight-resistant American chestnut trees through a single gene insertion, rather than deep genetic tinkering.

The company is inspired by saving American hardwoods that have been ravaged by an introduced fungal disease, and says their proprietary approach could be replicated to help save American elm, ash, and white oak trees as well.

North American timber is a $350 billion industry. Hardwood forests support habitats and biodiversity, and anchor some 15% of all American carbon. Yet between chestnut blight, the emerald ash borer, and Dutch elm disease, many native species have experienced catastrophic declines.

“I grew up in northern Ohio on a street called Chestnut Ridge, named by early settlers after the dominant trees on the landscape, so there was always a kind of mystique around the chestnut in the back of my memory, even before I understood why,” Andrew Serazin, co-founder of SilvaBio , told GNN in an email correspondence.

Several concepts for protecting or immunizing American chestnuts from the blight which landed on American shores in the early 1900s from East Asia have failed or are being tested. Along with his partner and aptly-named entrepreneur Michael Bloom, Serazin and SilvaBio have approached the challenge by combining sophisticated predictive methods and knowledge of the chestnut’s genomics with their “Lightspeed” breeding process that offers an enhanced form of propagation

The Darling 54 breakthrough was originally developed by scientists at the SUNY College of Environmental Science and Forestry (ESF). There, scientists inserted a single copy of a plant gene called OxO, which confers resilience to fungal diseases in a variety of plants from banana trees to mosses.

SilvaBio holds the exclusive license to this technology and continues to advance restoration by moving the Darling line from the lab to real-world deployment. Using genomic prediction, accelerated breeding, and advanced micropropagation, the company is developing a broad portfolio of American chestnut genetics designed to maximize diversity, adaptability, and long-term resilience.

“By analyzing DNA, we can identify which young seedlings are most likely to survive disease long before they would typically be tested in the field,” the co-founders told GNN. “In practice, this is similar to precision medicine, but applied to forests.”

“Through our proprietary speed-breeding process, carefully controlling high-intensity light, we can encourage trees to flower and reproduce much faster than they would in nature,” they continued. “This allows us to complete a breeding cycle in about a year, compared to 10 or more years using traditional approaches, overcoming one of the biggest bottlenecks in tree improvement.”

The result was “Darling54.” A double-blinded trial of this special American chestnut cultivar compared with common cultivars found that the “cankers” resulting from chestnut blight were orders of magnitude smaller on Darling54 both as a seedling and at 4 years.

More recently, 4 independent experiments from Purdue University, the University of New England, and SUNY, demonstrated that Darling American chestnut trees consistently show smaller blight cankers than their wild-type counterparts.

On Arbor Day 2026, a Darling54 chestnut was planted at the White House.